Determination of Nitroso Bumetanide in Bumetanide by LCMS-8045RX

Significance of the Topic

Bumetanide is a potent diuretic widely used to manage edema in patients with heart, liver, or kidney disorders. During its production, nitroso derivatives can form, posing carcinogenic or mutagenic risks. Sensitive and rapid detection of these impurities is crucial for ensuring drug safety and regulatory compliance.

Aims and Study Overview

This study establishes and validates a quantitative LC-MS/MS method using the Shimadzu LCMS-8045RX to detect nitroso bumetanide in the active pharmaceutical ingredient (API). The goal is to improve upon existing FDA recommendations by achieving greater sensitivity and shorter analysis times.

Methodology and Instrumentation

• Sample preparation: Dissolve bumetanide API at 1 mg/mL in methanol, filter through 0.22 μm, and prepare calibration standards from 0.2 to 100 ng/mL.
• Chromatography: Nexera-LC40B X3 system with Shim-pack Velox SP-C18 column (100×2.1 mm, 1.8 μm), 40 °C, 2 μL injection, gradient from 20% to 95% methanol over 8 min at 0.4 mL/min.
• Mass spectrometry: LCMS-8045RX in positive ESI mode, optimized MRM transitions for nitroso and parent ions, source temperatures (interface 350 °C, DL 250 °C, heat block 450 °C), and gas flows adjusted for signal stability. Probe position set at 4 mm.

Main Results and Discussion

• Sensitivity: LOD 0.2 ng/mL and LOQ 0.5 ng/mL, exceeding FDA nonbinding guidance of 1 ng/mL.
• Linearity: 0.2–100 ng/mL with R² > 0.998, accuracy between 91.2% and 105.3%.
• Precision: RSD of retention time < 0.07% and peak area < 5.4% across low, medium, and high concentrations.
• Recovery: 98.49%–101.85% recovery at spiking levels of 1 and 5 ng (n=3), RSD < 2.6%.
• Specificity: No detectable interference at the target retention time in blank matrix.
• Probe optimization: Demonstrated optimal balance of sensitivity and stability at a 4–5 mm spray needle distance.

Advantages and Practical Applications

• Fast throughput: 8 min per analysis, enabling high sample throughput.
• High sensitivity: Sub-ng/mL detection supports stringent impurity limits.
• Robustness: Stable performance minimizes downtime and maintenance.
• Regulatory alignment: Method meets or surpasses guideline requirements for nitrosamine control.

Future Trends and Potential Applications

• Extension to other nitrosamine impurities across diverse pharmaceutical compounds.
• Integration with automated sample preparation for fully streamlined workflows.
• Advances in ion source technology to further enhance sensitivity and reduce contamination.
• Application in complex biological matrices for pharmacokinetic and toxicological studies.

Conclusion

The validated LCMS-8045RX method delivers a rapid, accurate, and highly sensitive approach to quantify nitroso bumetanide in API. Its performance surpasses existing methods, reinforcing its suitability for quality control and regulatory monitoring in pharmaceutical manufacturing.